Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 2/3 1Phase 1/2 1

Status

Completed 179Recruiting 115Unknown 95Terminated 84Active not recruiting 46Not yet recruiting 34Withdrawn 26Enrolling by invitation 5Suspended 3

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5Observational 3

Sponsor

Cancer Type

Gastrointestinal 5CNS 1

Conditions

Neoplasms 40Breast Neoplasms 38Prostatic Neoplasms 24Colorectal Neoplasms 23Uterine Cervical Neoplasms 16Carcinoma, Non-Small-Cell Lung 13Anxiety Disorders 13Stomach Neoplasms 9Lymphoma, Follicular 9Leukemia, Myeloid, Acute 9Carcinoma, Hepatocellular 9Brain Neoplasms 9Lung Neoplasms 8Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Esophageal Neoplasms 7Sarcoma 6Ovarian Neoplasms 6Esophageal Squamous Cell Carcinoma 6Depression 6Colonic Neoplasms 6Uterine Cervical Dysplasia 5Small Cell Lung Carcinoma 5Pain 5Glioma 5Epilepsy 5Dementia 5Cholangiocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4

Interventions

futibatinib 1camrelizumab 1anlotinib 1S 1 (combination) 1Liver Transplantation 1Fulvestrant 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Enrolling by invitation × Interventional × Cholangiocarcinoma × Clear all
NCT06506955 2026-05-28

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Taiho Oncology, Inc.

Phase 2/3 Enrolling by invitation
15 enrolled
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT06963060 2025-05-08

GALENT-BT

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Enrolling by invitation
44 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT06901622 2025-03-30

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

The First Affiliated Hospital of Zhengzhou University

Phase 2 Enrolling by invitation
50 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT01868490 2025-02-10

The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells

Siriraj Hospital

Phase 1/2 Enrolling by invitation
20 enrolled
CNSGastrointestinal

Neuroblastoma, Cholangiocarcinoma

NCT04195503 2024-10-10

Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma

University Health Network, Toronto

Phase NA Enrolling by invitation
10 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡